1. Davidson MR, Gazdar AF, Clarke BE (2013) The pivotal role of pathology in the management of lung cancer. J Thorac Dis 5(Suppl 5):S463–S478
2. European Medicines Agency Keytruda: Pembrolizumab. London 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp . Zugegriffen: 10.05.2016
3. European Medicines Agency Opdivo: Nivolumab. London 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp . Zugegriffen: 10.05.2016
4. Galland F, Stefanova M, Lafage M, Birnbaum D (1992) Localization of the 5’ end of the MCF2 oncogene to human chromosome 15q15-q23. Cytogenet Cell Genet 60(2):114–116
5. Garon EB, Rizivi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028